Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis' Phase III trial of pelacarsen for lipoprotein(a) reduction failed to meet its primary cardiovascular endpoint. The drug reduced Lp(a) levels but did not lower cardiovascular risk. Novartis and Ionis developed the drug. Amgen and Lilly have competing Lp(a)-targeting drugs. Novartis and Amgen shares fell 3% and 5%, respectively, after the announcement.
How this was made
The 30-second read
Why it matters
The failure adds to recent setbacks for Novartis, increasing pressure on its pipeline and upcoming patent expirations.
Market read
Trial failure is a material event for Novartis and may influence sentiment toward Lp(a) therapeutic approaches.
What to watch
Potential for combination therapies or alternative indications for pelacarsen not addressed in this trial.
Background
Novartis holds global rights to pelacarsen via Ionis; the trial involved 8,323 patients with elevated Lp(a) and cardiovascular disease.
Ticker impact
Novartis reported its Phase III pelacarsen trial failed to meet the primary endpoint, causing a 3% stock drop.
short-term downside pressure, potential further decline if no remedial data emerges
Phase III failure is material for a large pharma; market reacts to trial outcomes promptly.
Market effects
May dampen investor enthusiasm for Lp(a) lowering therapies across biotech sector.
European pharma stocks could see modest pressure.
Highlights challenges in cardiovascular drug development worldwide.
Counterpoint
Some investors may view the modest Lp(a) reduction as a long-term opportunity if future data clarifies efficacy.
Key entities
- companyNovartis
Swiss pharmaceutical giant developing pelacarsen.
- companyIonis
Partner that discovered and initially developed pelacarsen.
